Navigation Links
Drug for pediatric brain cancer

Scientists from Canada are reporting promising results from a study of a new drug for children with acute brain tumors. The drug fotemustine, when delivered intravenously every three weeks, was found to be partially effective in shrinking the tumors.
//
The drug is one of a group of drugs called chloroethylnitrosoureas. They were first discovered in 1959 and have since been shown to help shrink solid tumors, including cancerous brain tumors. Studies in adults with brain tumors showed fotemustine was at least partially effective in about 20 percent of patients.

In this study, researchers from the Hospital for Sick Children in Toronto tested the drug in 14 children under age 20 with various types of malignant brain tumors, including primary tumors and tumors caused by cancer that had spread to the brain. All of the children had exhausted conventional.

Together the children received a total of 40 doses of the medication. Images were then taken to measure the response to the drug. Three children demonstrated a positive response to the drug, with one showing a 50 percent or greater reduction in the tumor and the other two showing 25% to 50% reductions. The drug was generally well-tolerated by the children.

The researchers believe these results indicate a need for further study of fotemustine for the treatment of pediatric brain tumors and suggest the need for more studies involving the drug alone or possibly in combination with other agents.


'"/>




Page: 1

Related medicine news :

1. Medicis Pharmaceutical company enters pediatric market
2. Drug for pediatric brain cancer
3. Lorenzos oil for prevention of pediatric neurological disorder
4. British pediatricians urge parents to administer MMR to children
5. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
6. Two doctors suspended for wrong brain surgery
7. The brain loves a surprise
8. Increase in sugar...decrease in brain function!!!
9. Alcohol shrinks brain
10. Roller coaster takes brain for a big ride!!
11. The big brain in suicides
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: